Loading...
| A01966 | Pages: 261 | May 2020 | 17745 Views | | |
| Author(s) : Sanjivan Gill and OnkarSumant | Tables: 113 | Charts: 80 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Blood Market
Request Now !The blood market accounted for $7,201 million in 2020, and is expected to reach $10,253 million by 2027, registering a CAGR of 4.5% from 2020 to 2027.
Blood is a highly essential body fluid, which is responsible for smooth functioning of organs. However, there are different chronic medical conditions that lead to lowering down of red blood cells in the body. For instance, diseases such as leukemia, cancer, and end stage renal disorders lead to serious complications, which require blood transfusion. Furthermore, other conditions, such as a trauma injury in which there is huge blood loss, require blood transfusion for treatment. In addition, major surgical procedures can also lead to blood loss and hence, require use of donated whole blood. Thus, there has been a rise in demand for whole blood, plasma, and its components. The collection of whole blood and plasma require use of various systems, consumables, and reagents. For instance, whole blood is collected using systems that are offered by the key players such as Haemonetics Corporation and Grifols, SA. Similarly, the collected blood is subjected to screening and testing, which, in turn, requires other type of systems and reagents. For instance, Procleix Tigris System offered by Grifols, SA is used for blood screening. Moreover, key players also offer reagents, which are used along with these systems to check the results of the tests performed.
Surge in demand for blood and plasma across the globe and rise in geriatric population worldwide are anticipated to boost the market growth. In addition, increase in blood and plasma donations across the globe and favorable government regulations for blood screening are some other factors that boost the growth of the market. Furthermore, advancements in blood transfusion and blood screening instruments is another major factor that drives the blood market growth. However, factors such as high cost of advanced blood collection devices and lack of skilled laboratory professionals hinder the growth of the market. Furthermore, developing economies offer lucrative growth opportunities for the market.
Get more information on this report : Request Sample Pages
The blood market is segmented into product, end user, and region. On the basis of product, it is classified into whole blood collection and processing, source plasma collection, blood typing products, and blood screening products. These segments are further classified into sub-segments. For instance, the whole blood collection segment is classified into whole blood collection systems and whole blood collection consumables. The source plasma collection segment is classified into source plasma collection systems and source plasma collection consumables. The blood typing products segmentisfurther bifurcated into blood typing systems and blood typing reagents. The blood screening products segment is divided into blood screening systems and blood screening reagents.
On the basis of end user, the blood market is divided into blood and blood component bank, diagnostic laboratories, ambulatory surgical centers, hospitals, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)
On the basis of product, the whole blood collection and processing segment acquired the major share of the market in 2019. Rise in demand for whole blood across the globe and surge in number of whole blood collection centers propel the growth of this segment. Furthermore, factors such as rise in number of blood banks also contribute to the growth of the market. In addition, the source plasma collection segment is expected to exhibit fastest growth rate during the forecast period, owing to surge in demand for plasma and rise in prevalence of chronic diseases, which require use of plasma for treatment such as chronic kidney diseases and liver diseases.
Get more information on this report : Request Sample Pages
By end user, the blood and blood component bank acquired the major share in the market, owing to surge in number of blood banks across the globe. Furthermore, large number of blood donations received by blood banks is another factor that contributes to the growth of the market. In addition, rise in demand for blood and plasma across the globe also boost the growth of the blood market.
Get more information on this report : Request Sample Pages
On the basis of region, North America occupied the largest blood market share in 2019, and is expected to maintain a dominant position during the forecast period, owing to factors such as easy availability of systems, reagents, and consumables used in whole blood collecting, processing, typing, and screening. Furthermore, other factors such as rise in awareness related to use of these products and presence of large number of blood collection and plasma collection centers across the region also contribute to the growth of the market. Moreover, presence of large number of key players in North America is another major factor that drives the growth of the market. However, Asia-Pacific is expected to register fastest growth during the forecast period, owing to surge in healthcare expenditure, and increase in awareness related to blood and plasma donation. Other factors that boost the growth of the market include huge patient base of various chronic diseases such as metabolic diseases, and cancer, which require the use of whole blood and plasma contribute to the growth of the blood market in Asia-Pacific.
Get more information on this report : Request Sample Pages
The global blood market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum blood market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Abbott Laboratories, Bio-Rad Laboratories, Inc., CSL Limited (CSL Behring), F. Hoffmann-La Roche Ltd., Grifols International SA, Haemonetics Corporation, Merck & Co., Inc., Novo Nordisk A/S, Ortho Clinical Diagnostics, and Terumo Corporation (Terumo BCT, Inc.).
This report entails a detailed quantitative analysis along with the current global blood market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
The blood market forecast is studied from 2020 to 2027.
The blood market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the blood market.
Key Market Segments
By Product
By End User
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top player positioning
3.2.1.Top investment pockets
3.3.Key forces shaping blood industry/Market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in demand for blood and other blood related products across the globe
3.4.1.2.Rise in geriatric population across the globe
3.4.1.3.Surge in blood donations and plasma donations across the globe
3.4.1.4.Favorable government regulations for blood screening
3.4.1.5.Advancements in blood transfusion and blood screening instruments
3.4.2.Restraints
3.4.2.1.High cost of advanced blood collection devices
3.4.2.2.Lack of skilled laboratory professionals
3.4.3.Opportunities
3.4.3.1.Developing economies offer lucrative growth opportunities
3.4.4.Impact Analysis
3.5.Blood Therapeutics
3.5.1.Key market trends, growth factors, and opportunities
3.5.2.Market size and forecast, by product
3.5.2.1.Intravenous Immunoglobulin
3.5.2.1.1.Market size and forecast
3.5.2.2.Factor IX
3.5.2.2.1.Market size and forecast
3.5.2.3.Factor VIII
3.5.2.3.1.Market size and forecast
3.5.2.4.Albumin
3.5.2.4.1.Market size and forecast
3.5.2.5.Hyperimmune
3.5.2.5.1.Market size and forecast
3.5.2.6.Others
3.5.2.6.1.Market size and forecast
3.5.3.Market size and forecast, by region
CHAPTER 4:BLOOD MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Whole blood collection and processing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Whole Blood Collection and Processing Systems
4.2.2.1.1.Market size and forecast
4.2.2.1.2.Market size and forecast, by region
4.2.2.2.Whole Blood Collection and Processing Consumables
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by region
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Source plasma collection
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Source Plasma Collection Systems
4.3.2.1.1.Market size and forecast
4.3.2.1.2.Market size and forecast, by region
4.3.2.2.Source Plasma Collection Consumables
4.3.2.2.1.Market size and forecast
4.3.2.2.2.Market size and forecast, by region
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Blood typing products
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Blood Typing Systems
4.4.2.1.1.Market size and forecast
4.4.2.1.2.Market size and forecast, by region
4.4.2.2.Blood Typing Reagents
4.4.2.2.1.Market size and forecast
4.4.2.2.2.Market size and forecast, by region
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Blood screening products
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Blood Screening Systems
4.5.2.1.1.Market size and forecast
4.5.2.1.2.Market size and forecast, by region
4.5.2.2.Blood Screening Reagents
4.5.2.2.1.Market size and forecast
4.5.2.2.2.Market size and forecast, by region
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
CHAPTER 5:BLOOD MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Blood and blood component bank
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Diagnostic laboratories
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Ambulatory surgical centers
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Hospitals
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:BLOOD MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market analysis, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. blood market size and forecast, by product
6.2.2.1.2.U.S. blood market size and forecast, by end user
6.2.2.2.Canada
6.2.2.2.1.Canada blood market size and forecast, by product
6.2.2.2.2.Canada blood market size and forecast, by end user
6.2.2.3.Mexico
6.2.2.3.1.Mexico blood market size and forecast, by product
6.2.2.3.2.Mexico blood market size and forecast, by end use
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by end user
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market analysis, by country
6.3.2.1.Germany
6.3.2.1.1.Germany blood market size and forecast, by product
6.3.2.1.2.Germany blood market size and forecast, by end user
6.3.2.2.France
6.3.2.2.1.France blood market size and forecast, by product
6.3.2.2.2.France blood market size and forecast, by end user
6.3.2.3.UK
6.3.2.3.1.UK blood market size and forecast, by product
6.3.2.3.2.UK blood market size and forecast, by end user
6.3.2.4.Italy
6.3.2.4.1.Italy blood market size and forecast, by product
6.3.2.4.2.Italy blood market size and forecast, by end user
6.3.2.5.Spain
6.3.2.5.1.Spain blood market size and forecast, by product
6.3.2.5.2.Spain blood market size and forecast, by end user
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe blood market size and forecast, by product
6.3.2.6.2.Rest of Europe blood market size and forecast, by end user
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by end user
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market analysis, by country
6.4.2.1.Japan
6.4.2.1.1.Japan blood market size and forecast, by product
6.4.2.1.2.Japan blood market size and forecast, by end user
6.4.2.2.China
6.4.2.2.1.China blood market size and forecast, by product
6.4.2.2.2.China blood market size and forecast, by end user
6.4.2.3.Australia
6.4.2.3.1.Australia blood market size and forecast, by product
6.4.2.3.2.Australia blood market size and forecast, by end user
6.4.2.4.India
6.4.2.4.1.India blood market size and forecast, by product
6.4.2.4.2.India blood market size and forecast, by end user
6.4.2.5.South Korea
6.4.2.5.1.South Korea blood market size and forecast, by product
6.4.2.5.2.South Korea blood market size and forecast, by end user
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific blood market size and forecast, by product
6.4.2.6.2.Rest of Asia-Pacific blood market size and forecast, by end user
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by end user
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market analysis, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil blood market size and forecast, by product
6.5.2.1.2.Brazil blood market size and forecast, by end user
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia blood market size and forecast, by product
6.5.2.2.2.Saudi Arabia blood market size and forecast, by end user
6.5.2.3.South Africa
6.5.2.3.1.South Africa blood market size and forecast, by product
6.5.2.3.2.South Africa blood market size and forecast, by end user
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA blood market size and forecast, by product
6.5.2.4.2.Rest of LAMEA blood market size and forecast, by end user
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.1.2.1. Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BIO-RAD LABORATORIES, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.CSL LIMITED (CSL BEHRING)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.F. HOFFMANN-LA ROCHE LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS INTERNATIONAL SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.HAEMONETICS CORPORATION
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MERCK & CO., INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.NOVO NORDISK A/S
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.ORTHO CLINICAL DIAGNOSTICS
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Key strategic moves and developments
7.10.TERUMO CORPORATION (TERUMO BCT, INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY TYPE 2019–2027 ($MILLION)
TABLE 02.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY REGION 2019–2027 ($MILLION)
TABLE 03.GLOBAL BLOOD MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY TYPE 2019–2027 ($MILLION)
TABLE 05.WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 06.WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 07.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY REGION, 2019–2027 ($MILLION)
TABLE 08.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY TYPE 2019–2027 ($MILLION)
TABLE 09.SOURCE PLASMA COLLECTION SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 10.PLASMA COLLECTION CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 11.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 13.BLOOD TYPING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 14.BLOOD TYPING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 15.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 16.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 17.BLOOD SCREENING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 18.BLOOD SCREENING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 19.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.GLOBAL BLOOD MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 21.BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY REGION 2019–2027($MILLION)
TABLE 22.BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION 2019–2027($MILLION)
TABLE 23.BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION 2019–2027($MILLION)
TABLE 24.BLOOD MARKET FOR HOSPITALS, BY REGION 2019–2027($MILLION)
TABLE 25.BLOOD MARKET FOR OTHERS , BY REGION 2019–2027($MILLION)
TABLE 26.BLOOD MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 27.SCREENING OF DONATED BLOOD IN U.S.
TABLE 28.NORTH AMERICA BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 29.U.S. BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 30.U.S. BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 31.CANADA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 32.CANADA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 33.MEXICO BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 34.MEXICO BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 35.NORTH AMERICA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 36.NORTH AMERICA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 37.EUROPE BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 38.GERMANY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 39.GERMANY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 40.FRANCE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 41.FRANCE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 42.UK BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 43.UK BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 44.ITALY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 45.ITALY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 46.SPAIN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 47.SPAIN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 48.REST OF EUROPE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 49.REST OF EUROPE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 50.EUROPE BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 51.EUROPE BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 52.ASIA-PACIFIC BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 53.JAPAN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 54.JAPAN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 55.CHINA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 56.CHINA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 57.AUSTRALIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 58.AUSTRALIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 59.INDIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 60.INDIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 61.SOUTH KOREA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 62.SOUTH KOREA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 66.ASIA-PACIFIC BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 67.MIDDLE EAST BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 68.BRAZIL BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 69.BRAZIL BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 70.SAUDI ARABIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 71.SAUDI ARABIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 72.SOUTH AFRICA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 73.SOUTH AFRICA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 74.REST OF LAMEA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 75.REST OF LAMEA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 76.LAMEA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 77.LAMEA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 78.ABBOTT: COMPANY SNAPSHOT
TABLE 79.ABBOTT: OERATING SEGMENT
TABLE 80.ABBOTT: PRODUCT PORTFOLIO
TABLE 81.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82.BIO-RAD: COMPANY SNAPSHOT
TABLE 83.BIO-RAD: OERATING SEGMENT
TABLE 84.BIO-RAD: PRODUCT PORTFOLIO
TABLE 85.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 86.CSL: COMPANY SNAPSHOT
TABLE 87.CSL: OERATING SEGMENT
TABLE 88.CSL: PRODUCT PORTFOLIO
TABLE 89.ROCHE: COMPANY SNAPSHOT
TABLE 90.ROCHE: OERATING SEGMENT
TABLE 91.ROCHE: PRODUCT PORTFOLIO
TABLE 92.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.GRIFOLS: COMPANY SNAPSHOT
TABLE 94.GRIFOLS: OERATING SEGMENT
TABLE 95.GRIFOLS: PRODUCT PORTFOLIO
TABLE 96.GRIFOLS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.HAEMONETICS: COMPANY SNAPSHOT
TABLE 98.HAEMONETICS: OPERATING SEGMENTS
TABLE 99.HAEMONETICS: PRODUCT PORTFOLIO
TABLE 100.HAEMONETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.MERCK: COMPANY SNAPSHOT
TABLE 102.MERCK: OPERATING SEGMENTS
TABLE 103.MERCK PRODUCT PORTFOLIO
TABLE 104.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 105.NOVO NORDISK: OERATING SEGMENT
TABLE 106.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 107.NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108.ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 109.ORTHO CLINICAL DIAGNOSTICS.: PRODUCT PORTFOLIO
TABLE 110.ORTHO CLINICAL DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111.TERUMO: COMPANY SNAPSHOT
TABLE 112.TERUMO: OERATING SEGMENT
TABLE 113.TERUMO: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL BLOOD MARKET SEGMENTATION
FIGURE 02.TOP PLAYER POSITIONING, 2018
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
FIGURE 06.LOW THREAT OF SUBSTITUTES
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.MODERATE THREAT OF NEW ENTRANT
FIGURE 09.GERIATRIC POPULATION (%), 2017-2018
FIGURE 10.IMPACT ANALYSIS, BLOOD MARKET
FIGURE 11.BLOOD THERAPEUTICS MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, 2019–2027 ($MILLION)
FIGURE 12.BLOOD THERAPEUTICS MARKET FOR FACTOR IX, 2019–2027 ($MILLION)
FIGURE 13.BLOOD THERAPEUTICS MARKET FOR FACTOR VIII, 2019–2027 ($MILLION)
FIGURE 14.BLOOD THERAPEUTICS MARKET FOR ALBUMIN, 2019–2027 ($MILLION)
FIGURE 15.BLOOD THERAPEUTICS MARKET FOR HYPERIMMUNE, 2019–2027 ($MILLION)
FIGURE 16.BLOOD THERAPEUTICS MARKET FOR OTEHRS, 2019–2027 ($MILLION)
FIGURE 17.WHOLE BLOOD COLLECTION AND PROCESSING MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 18.WHOLE BLOOD COLLECTION AND PROCESSING MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR WHOLE BLOOD COLLECTION, BY COUNTRY, 2019 & 2027(%)
FIGURE 20.COMPOSITION OF PLASMA
FIGURE 21.PLASMA COLLECTION MARKET FOR SOURCE PLASMA COLLECTION SYSTEMS, 2019–2027 ($MILLION)
FIGURE 22.PLASMA COLLECTION MARKET FOR SOURCE PLASMA COLLECTION CONSUMABLES, 2019–2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY COUNTRY, 2019 & 2027(%)
FIGURE 24.BLOOD TYPING MARKET FOR BLOOD TYPING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 25.BLOOD TYPING MARKET FOR BLOOD TYPING REAGENTS, 2019–2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY COUNTRY, 2019 & 2027(%)
FIGURE 27.BLOOD SCREENING MARKET FOR BLOOD TYPING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 28.BLOOD SCREENING MARKET FOR BLOOD SCREENING REAGENTS, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY COUNTRY, 2019 & 2027(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 34.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 35.U.S. BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 36.CANADA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 37.MEXICO BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 38.GERMANY BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 39.FRANCE BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 40.UK BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 41.ITALY BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 42.SPAIN BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 43.REST OF EUROPE BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 44.JAPAN BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 45.CHINA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 46.AUSTRALIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 47.INDIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 48.SOUTH KOREA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 49.REST OF ASIA-PACIFIC BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 50.BRAZIL BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 51.SAUDI ARABIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 52.SOUTH AFRICA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 53.REST OF LAMEA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 54.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 56.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 57.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 59.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.CSL: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.CSL: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 62.CSL: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 63.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 65.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.GRIFOLS: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.GRIFOLS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 68.GRIFOLS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 69.HAEMONETICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 70.HAEMONETICS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 71.HAEMONETICS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 72.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.MERCK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 74.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 75.NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 76.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 77.NOVO NORDISK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 78.TERUMO: NET SALES, 2017–2019 ($MILLION)
FIGURE 79.TERUMO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 80.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)
The utilization of systems, reagents, and consumables is anticipated to witness a significant rise with surge in blood and plasma donations across the globe. Furthermore, increase in demand for whole blood and plasma, rise in number of blood and plasma collection centers worldwide contribute to the growth of the market. Moreover, surge in geriatric population and increase in the incidence of trauma and casualties, and technological advancements are some of the other major factors that drive the market growth.
In addition, North America held the largest share in the market due to increase in investments made by large medical diagnostic product manufacturing companies in R&D for development of advanced blood tests in this region. Moreover, well-equipped hospitals and clinics for the treatment of increased number of patients suffering from various chronic diseases and high level of awareness among people about blood donation in the region are responsible for the growth of the blood market.
A. The total market value of blood market is $777.12 million in 2019.
A. The forcast period for blood market is 2020 to 2027
A. The market value of blood market in 2019 is $828.85 million.
A. The base year is 2019 in blood market
A. Top companies such as, Grifols International SA., Haemonetics Corporation, Terumo Corporation (Terumo BCT, Inc.), CSL Limited (CSL Behring), and Bio-Rad Laboratories, Inc held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Source plasma collection is the most influencing segment owing to surge in plasma donations across the globe. Furthermore, rise in prevalence of chronic disorders that require the use of plasma is another major factor that contributes to the growth of the blood market
A. The major factor that fuels the growth of the global blood market includes rise in demand for blood and other blood related products across the globe. This leads to surge in demand for blood collection, screening, processing and typing reagents and systems which contribute to the growth of the market.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 7.8%. This is due to due to rise in number of patients suffering from chronic diseases and improving healthcare facilities in the region.
A. There are various steps followed by blood industry to make blood available for ens users. Thus, different systems and reagents are used at every step, for instnace, blood collection requires the use of devices such as apheresis machine, blood screening requires the use of reagents and others.
A. The devices are used to carry out various steps in the process of making blood, plasma and their components available to the market. For instance, these machines are employed in collection of whole blood, screening of the collected blood for identification fo infection markers, grouping of blood and others.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
